Clinical TrialsInterim data from Phase 1 development for NBD1 stabilizers '719 and '451 is promising, with complete dosing and full data expected soon.
Financial PerformanceSION ended 1Q25 with $354.7M cash, including net proceeds of $199.6M from the recent successful IPO, providing operating expense runway into 2028.
Pipeline DevelopmentSION's NBD1 drug candidates may normalize CFTR function in combo therapy with SOC, or with SION's own CFTR modulators.